Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Free Cash Flow (2016 - 2025)

Bio-Techne has reported Free Cash Flow over the past 17 years, most recently at $76.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $76.5 million for Q4 2025, down 1.34% from a year ago — trailing twelve months through Dec 2025 was $223.0 million (down 12.3% YoY), and the annual figure for FY2025 was $256.6 million, up 8.66%.
  • Free Cash Flow for Q4 2025 was $76.5 million at Bio-Techne, up from $22.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TECH hit a ceiling of $110.7 million in Q2 2021 and a floor of $22.2 million in Q3 2025.
  • Median Free Cash Flow over the past 5 years was $61.3 million (2021), compared with a mean of $63.1 million.
  • Biggest five-year swings in Free Cash Flow: surged 303.76% in 2021 and later plummeted 59.39% in 2025.
  • Bio-Techne's Free Cash Flow stood at $90.8 million in 2021, then tumbled by 35.84% to $58.3 million in 2022, then grew by 17.12% to $68.3 million in 2023, then grew by 13.59% to $77.5 million in 2024, then fell by 1.34% to $76.5 million in 2025.
  • The last three reported values for Free Cash Flow were $76.5 million (Q4 2025), $22.2 million (Q3 2025), and $93.3 million (Q2 2025) per Business Quant data.